Summit Therapeutics Plc Stock Fundamentals
| SMMT Stock | USD 18.94 0.26 1.35% |
Summit Therapeutics PLC fundamentals help investors to digest information that contributes to Summit Therapeutics' financial success or failures. It also enables traders to predict the movement of Summit Stock. The fundamental analysis module provides a way to measure Summit Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Summit Therapeutics stock.
At this time, Summit Therapeutics' Depreciation And Amortization is comparatively stable compared to the past year. Interest Expense is likely to gain to about 17.3 M in 2024, despite the fact that Operating Income is likely to grow to (85.2 M). Summit | Select Account or Indicator |
Summit Therapeutics PLC Company Return On Equity Analysis
Summit Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Summit Therapeutics Return On Equity | -0.73 |
Most of Summit Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Summit Therapeutics PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Summit Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Summit Therapeutics PLC has a Return On Equity of -0.7321. This is 96.95% lower than that of the Biotechnology sector and 97.99% lower than that of the Health Care industry. The return on equity for all United States stocks is 136.16% higher than that of the company.
Summit Therapeutics PLC Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Summit Therapeutics's current stock value. Our valuation model uses many indicators to compare Summit Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Summit Therapeutics competition to find correlations between indicators driving Summit Therapeutics's intrinsic value. More Info.Summit Therapeutics PLC is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Summit Therapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Summit Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Summit Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Summit Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Summit Therapeutics could also be used in its relative valuation, which is a method of valuing Summit Therapeutics by comparing valuation metrics of similar companies.Summit Therapeutics is currently under evaluation in return on equity category among its peers.
Summit Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Summit Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Summit Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Summit Fundamentals
| Return On Equity | -0.73 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | 13.51 B | ||||
| Shares Outstanding | 737.45 M | ||||
| Shares Owned By Insiders | 84.36 % | ||||
| Shares Owned By Institutions | 11.75 % | ||||
| Number Of Shares Shorted | 15.99 M | ||||
| Price To Earning | 2.85 X | ||||
| Price To Book | 31.89 X | ||||
| Price To Sales | 753.90 X | ||||
| Gross Profit | 705 K | ||||
| EBITDA | 1 M | ||||
| Net Income | (614.93 M) | ||||
| Cash And Equivalents | 121.97 M | ||||
| Cash Per Share | 0.61 X | ||||
| Total Debt | 106.1 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 8.22 X | ||||
| Book Value Per Share | 0.59 X | ||||
| Cash Flow From Operations | (76.76 M) | ||||
| Short Ratio | 6.96 X | ||||
| Earnings Per Share | (0.23) X | ||||
| Target Price | 27.03 | ||||
| Number Of Employees | 105 | ||||
| Beta | -0.92 | ||||
| Market Capitalization | 13.97 B | ||||
| Total Asset | 202.95 M | ||||
| Retained Earnings | (993.26 M) | ||||
| Working Capital | 169.31 M | ||||
| Current Asset | 20.86 M | ||||
| Current Liabilities | 3.21 M | ||||
| Net Asset | 202.95 M |
About Summit Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Summit Therapeutics PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Summit Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Summit Therapeutics PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 14.2 M | 14.9 M | |
| Cost Of Revenue | 2 M | 1.9 M | |
| Stock Based Compensation To Revenue | 12.63 | 13.26 | |
| Sales General And Administrative To Revenue | 34.12 | 35.83 | |
| Research And Ddevelopement To Revenue | 66.45 | 69.77 | |
| Capex To Revenue | 1.02 | 0.86 | |
| Ebit Per Revenue | (117.71) | (111.82) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Summit Stock Analysis
When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.